CN107043413A - A kind of related urinary biomarkers albumen of pulmonary tuberculosis and its application - Google Patents

A kind of related urinary biomarkers albumen of pulmonary tuberculosis and its application Download PDF

Info

Publication number
CN107043413A
CN107043413A CN201610084080.2A CN201610084080A CN107043413A CN 107043413 A CN107043413 A CN 107043413A CN 201610084080 A CN201610084080 A CN 201610084080A CN 107043413 A CN107043413 A CN 107043413A
Authority
CN
China
Prior art keywords
urine
pulmonary tuberculosis
protein
albumen
rbp4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610084080.2A
Other languages
Chinese (zh)
Inventor
郭爱珍
王洁茹
熊学凯
朱小洁
刘晗
葛盼
陈颖钰
胡长敏
陈曦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huazhong Agricultural University
Original Assignee
Huazhong Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huazhong Agricultural University filed Critical Huazhong Agricultural University
Priority to CN201610084080.2A priority Critical patent/CN107043413A/en
Publication of CN107043413A publication Critical patent/CN107043413A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention belongs to biochemical immunity analysis technical field, and in particular to a kind of related urinary biomarkers albumen of pulmonary tuberculosis and its application.The present invention obtains two kinds of pulmonary tuberculosis correlation Urine proteins, i.e. Urine proteins RBP ELISA RBP4, the protein sequence such as sequence table SEQ ID NO of the albumen using protein science screening:Shown in 1.The Urine proteins of the present invention can be used as mark antigen protein application in detection pulmonary tuberculosis Urine in Diagnosis kit is prepared.

Description

A kind of related urinary biomarkers albumen of pulmonary tuberculosis and its application
Technical field
The invention belongs to biochemical immunity analysis technical field, and in particular to the related urinary biomarkers albumen of a kind of pulmonary tuberculosis and its should With.
Background technology
Tuberculosis is a kind of zoonosis as caused by M.tuberculosis complex, with higher infection rate and death toll, is arranged For after HIV the whole world cause death second largest infectious disease.It is largely because not to fail lungy spread of control (so that effectively treating) cases of infection can fully be detected.Therefore, the one of the global Stop TB plan of the World Health Organization is big Emphasis is that development is simple, inexpensive and effective new diagnostic methods, to improve existing detection case.In the feelings of resource-constrained Under condition, active diagnosing tuberculosis.Clinical assessment is relied primarily on, and combines sediments microscope inspection Sputum smears;Separated from clinical sample It is always diagnosis of tuberculosis goldstandard to cultivate mycobacterium tuberculosis, however, this standard is costly, time-consuming, recall rate is low, and is needed Bio-safety facility that will be stricter.Therefore, it is to study the key areas of tuberculosis prevention and treatment to find tuberculosis new diagnostic mark.
The development of diagnosis of tuberculosis method is hindered due to lacking reliable and by checking MTB biomarkers at present.Therefore manage The tuberculosis laboratory diagnostic method thought should possess it is following some:(1) sensitivity and specificity are high;(2) cost is low;(3) can Early detection and treatment Prognosis scoveillance;(4) detection spectrum is wide, including can detect smear for microscopic examination feminine gender or resistance case;(5) Sampling is simple, it is therefore desirable to which not damaged is sampled;(6) it is easy to detect, be conducive to carrying out field and domestic medicine service to tuberculosis.Just In the case of often, protein is few in urine, therefore, in urine kinds of protein and number change have occur with disease, development and Prognosis is relevant;Meanwhile, urine non-invasively can be obtained largely, and more stable for other biofluids, therefore Urinary proteomics are turning into an important content during Clinical Proteomics are studied, be it in scientific research and clinically Using laying a good foundation.
In the present invention, two dimensional electrophoresis and immunoblotting assay show, RBP4 albumen has significance difference in pulmonary tuberculosis and Healthy People urine Different expression, this show these protein can as pulmonary tuberculosis urine potential source biomolecule marker.RBP4 protein functions are significant, Because this material may take part in macrophage activation;RBP4 is also considered as being used to resist insulin as Adipocyte Factor, this Pathophysiological process may be adjusted during bacterium infection.And have been reported that display RBP4 participates in playing important work in immune response With, but this area does not know its specific influence situation that pulmonary tuberculosis is immunized still, also without it in lunger's urine Research and development.
The content of the invention
Present invention aims to overcome that the defect of prior art, i.e., detect pulmonary tuberculosis using the disease specific of Urine proteins there is provided one kind Relevant urinary biomarkers albumen, the marker protein can be used for lunger's Urine proteins biological marker, set up lunger (retinol-binding protein 4, RBP4, sequence is shown in SEQ ID NO to Urine proteins RBP ELISA:1) express, be lung Tuberculosis diagnosis in time and treatment provide support.
Present invention firstly discovers that Urine proteins especially RBP ELISA is examined as an important biological indicator in tuberculosis clinic It is disconnected, there is the effect of marker protein, the research for later tubercular's Urine proteins provides theory in antidiastole, effectively observation Foundation, and to provide new thought from molecular level diagnosis of tuberculosis, with great theory significance and potential use value.
The present invention is achieved through the following technical solutions:
A kind of detection method of pulmonary tuberculosis Urine proteins, comprises the following steps:
The total protein in lunger and Healthy People control urine is extracted using TCA/ acetone methods, and uses quantification of protein kit (Bio-Rad, USA) is quantified.Using two dimensional electrophoresis [1], MADEL-TOF-MS and immunoprecipitation method [1] are to pulmonary tuberculosis The Urine proteins that patient and Healthy People control have been extracted carry out separation identification, analyze expressed differential proteins, and identification can be used for pulmonary tuberculosis to suffer from The urine markers protein of person's diagnosis.
Present invention firstly discovers that a kind of Urine proteins RBP ELISA (retinol-binding protein 4, RBP4, P02753-HUMAN) as an important urine biology Testing index, in the diagnosis of pulmonary tuberculosis, antidiastole, effectively Effect in observation, foundation is provided for the research of pulmonary tuberculosis Urine proteins from now on, and from the horizontal Diagnosis of pulmonary knot of urine protein molecular Core disease provides new direction, with important theory value and potential Practical significance.
Pulmonary tuberculosis Urine proteins biomarker protein prepared by the present invention can be applied in pulmonary tuberculosis urine detection kit is prepared.
Brief description of the drawings
Sequence table SEQ ID NO:1 is the protein sequence for the Urine proteins RBP ELISA RBP4 that the present invention is separated.
Fig. 1:Differential expression of the Urine proteins in lunger and normal healthy controls person.
Fig. 2:Lunger and the clustering of normal healthy controls person's Urine proteins.
Fig. 3:Immunoprecipitation verifies differential expressions of the RBP4 in lunger and normal healthy controls person.
Embodiment
The examination embodiment in pulmonary tuberculosis patient to RBP4 albumen of embodiment 1
(1) collection and preparation of urine standard
Urine specimen comes from Wuhan City medical treatment center, according to various means such as clinical diagnosis, X images, Phlegm incubations, It is defined as activity lung pulmonary tuberculosis, and excludes AIDS, the patient newly accepted for medical treatment of disease of urinary tract.76 people successively are have collected, Everyone collects 30-50mL urina sanguinis mud-stream urines every time.Normal healthy controls urine specimen is collected simultaneously.
(2) urine specimen processing and the optimization of protein extracting method
Carried out the optimization of sample process condition, it is determined that processing routine be:Urine specimen adds protease inhibitors and (is purchased from sieve Family name company), centrifugation removes cell fragment and impurity, 3kDa ultrafiltration through membranes concentration, with TCA- acetone methods [2] protein precipitation, dialysis Desalination obtains purifying protein, reaches two dimensional electrophoresis albumen loading standard.
(3) Urine proteins two dimensional electrophoresis
To adhesive tape pH scopes, sample-loading buffer, adhesive tape equilibrium liquid, etc. point focusing program, SDS-PAGE concentration and voltage are carried out Condition optimizing, finally determines with that pH3-10 is non-linear, the linear adhesive tape of pH4-7 carries out two dimensional electrophoresis;The system of sample-loading buffer It is standby:8M urea, 2M thiocarbamides, 0.5% (w/v) propane sulfonic acid inner salt, 0.52% (w/v) ampholytes (pH310), the sulphur threoses of 60mM bis- Alcohol, 40mM trishydroxymethylaminomethane and 0.01% bromophenol blue;Adhesive tape equilibrium liquid be mother liquor (w/v) dithiothreitol (DTT) that adds 2% and 2.5% (w/v) iodacetyl ammonia, respectively balances 15min;Choose 10%SDS-PAGE;SDS-PAGE voltages 50V, 30min, 200V, 6h;Etc. point focusing program such as table 1.
The Urine proteins two dimensional electrophoresis program of table 1
Program Voltage Time
Aquation 50V 16h
S1 250V 3h
S2 1000V 6h
S3 10000V 3h
S4 10000V 60000VH
S5 500V 8h
Lunger and control group crowd's Urine proteins do two dimensional electrophoresis respectively, using PDQuest 8.0 (Bio-Rad) software point Analysis differential protein carries out MADEL-TOF-MS analyses to it, obtains 19 protein sequences, has carried out bioinformatic analysis and mirror Fixed, obtaining 1 has the host protein of potential mark meaning and to this difference Urine proteins (retinol-binding protein 4, RBP4, its sequence is shown in SEQ ID NO:1;P02753-HUMAN)
(4) verified using immunoprecipitate
Collect the urine of 25 lungers (5 one group of people, totally 5 groups) and 25 Healthy Peoples (5 one group of people, totally 5 groups) Liquid, uniformly mixes concentration, carries out Western Blot analyses, experimental verification RBP4 albumen is in pulmonary tuberculosis human urine Differential expression, and carry out statistical analysis using Image J softwares.As a result Fig. 3 is seen.
5. result of the test
1) general features of research object, the results are shown in Table 2.
The case-control crowd characteristic of table 2 is distributed
2) expression of the RBP4 albumen in lunger and control group and its diagnostic value to lung pulmonary tuberculosis:
Such as Fig. 1:The present invention is altogether to using two dimensional electrophoresis and MADEL-TOF-MS in 29 consumptives and 7 normal healthy controls persons Verify this Urine proteins.MADEL-TOF-MS is carried out to it using (Bio-Rad) the software analysis differential proteins of PDQuest 8.0 Analysis, obtains 19 protein sequences, has further carried out bioinformatic analysis and immunoprecipitate identification, and the present invention is obtained RBP4 has the host protein of potential mark meaning, while having carried out variance analysis to RBP4 albumen.As a result show that this RBP4 urinates There is significant difference between the two groups in the expression of albumen.
In the checking of Image J gray analysis immunoprecipitation, expression of the RBP4 Urine proteins in consumptive is right higher than health According to 3.82 times of person.The testing result that the mark albumen for relying on the present invention is obtained further illustrates the index of this Urine proteins to pulmonary tuberculosis The examination of disease has certain diagnostic value, and albumen of the invention can detect the diagnostic kit of pulmonary tuberculosis for preparation The middle application as antigen protein.
The RBP4 albumen of the present invention of embodiment 2 application of the sandwich ELISA in the diagnostic kit for preparing detection pulmonary tuberculosis
The clonal expression of 1.RBP4 albumen
According to SEQ ID NO disclosed by the invention:Sequence shown in 1, clones RBP4 genes, and in expression in escherichia coli, Obtain target antigen albumen;Recombinant protein further is extracted using affinity chromatography (according to a conventional method), the restructuring target for obtaining purifying resists Former rRBP4 (or recombinant protein rRBP4);
2. it is prepared by recombinant protein rRBP4 monoclonal antibody and polyclonal antibody
Antibody is prepared (referring to document 3,4) according to a conventional method, including:RRBP4 immunizing rabbits will be purified, rabbit-anti RBP4 is obtained Antibody;Immune mouse, obtains the anti-RBP4 monoclonal antibodies of mouse (monoclonal antibody and the reference of the preparation method of polyclonal antibody simultaneously: Zhu Li equalitys,《Immunology common experimental method》, People's Medical Officer Press, the method reported in 2000 editions and Xue Qingshan,《Body The philosophy and technique of outer culture》, Science Press, the method reported in version for 2001);
3. set up detection RBP4 sandwich ELISA
The anti-rRBP4 of mouse monoclonal antibody is coated with ELISA, closed with 5% defatted milk, the urine containing RBP4 or other body fluid For sample to be tested, rabbit-anti rRBP4 is detection antibody, and HRP- goat-antis rabbit (commercialization reagent) is secondary antibody, and TMB/H2O2 is substrate, HF terminating reactions, OD value (OD is detected with ELIASA at wavelength 630nm630).Make standard with the rRBP4 of above-mentioned purifying bent Line, using healthy negative human urine mean protein values ± 2~3SD as threshold value, sets up urine RBP4 detection sandwich ELISAs, further group Dress up kit.Kit component is as follows:
(1) one piece of elisa plate (being coated with the anti-rRBP4 polyclonal antibodies of mouse)
(2) rRBP4 positive criteria products (dried frozen aquatic products)
(3) sample diluting liquid (conventional formulation) and cleaning solution (conventional formulation)
(4) rabbit-anti rRBP4 polyclonal antibodies
(5) HRP- goat-antis rabbit secondary antibody
(6) nitrite ion (conventional formulation) and terminate liquid (conventional formulation)
Bibliography:
1.Rembert Pieper,Christine L.Gatlin,et al(2004)Characterization of the human urinary proteome:A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400distinct protein spots.Proteomics,4:1159–1174.
2.Chih-Ming Lu1,Yu-Jen Wu et al(2011)Identification of low-abundance proteins via fractionation of the urine proteome with weak anion exchange chromatography.Proteome Science,9:17.
3. Zhu Li equalitys,《Immunology common experimental method》, People's Medical Officer Press, 2000 editions
4. Xue Qing is apt to,《The philosophy and technique of in vitro culture》, Science Press, version in 2001.

Claims (2)

1. a kind of Urine proteins RBP ELISA RBP4, its protein sequence such as SEQ ID NO:Shown in 1.
2. the Urine proteins RBP ELISA described in claim 1 is in detection pulmonary tuberculosis urine reagent box is prepared as mark The application of will antigen protein.
CN201610084080.2A 2016-02-05 2016-02-05 A kind of related urinary biomarkers albumen of pulmonary tuberculosis and its application Pending CN107043413A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610084080.2A CN107043413A (en) 2016-02-05 2016-02-05 A kind of related urinary biomarkers albumen of pulmonary tuberculosis and its application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610084080.2A CN107043413A (en) 2016-02-05 2016-02-05 A kind of related urinary biomarkers albumen of pulmonary tuberculosis and its application

Publications (1)

Publication Number Publication Date
CN107043413A true CN107043413A (en) 2017-08-15

Family

ID=59543653

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610084080.2A Pending CN107043413A (en) 2016-02-05 2016-02-05 A kind of related urinary biomarkers albumen of pulmonary tuberculosis and its application

Country Status (1)

Country Link
CN (1) CN107043413A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024092169A3 (en) * 2022-10-27 2024-06-06 Cz Biohub Sf, Llc Lower respiratory tract infections

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101960309A (en) * 2008-01-17 2011-01-26 东丽株式会社 Composition and method for diagnosis or detection of gastric cancer
CN102196823A (en) * 2008-09-12 2011-09-21 日东电工株式会社 Imaging agents of fibrotic diseases
CN102388307A (en) * 2008-11-12 2012-03-21 耶达研究与发展有限公司 Diagnosis of multiple sclerosis
CN102405236A (en) * 2009-02-19 2012-04-04 葛兰素集团有限公司 Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
CN102812348A (en) * 2009-12-22 2012-12-05 新加坡科技研究局 SERS-based Analyte Detection
CN103025890A (en) * 2010-04-06 2013-04-03 卡里斯生命科学卢森堡控股 Circulating biomarkers for disease
CN103237901A (en) * 2010-03-01 2013-08-07 卡里斯生命科学卢森堡控股有限责任公司 Biomarkers for theranostics
CN105683757A (en) * 2013-08-20 2016-06-15 开普敦大学 Method for diagnosing tuberculosis in urine samples
CN106164089A (en) * 2014-04-02 2016-11-23 日东电工株式会社 Targeted molecular and application thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101960309A (en) * 2008-01-17 2011-01-26 东丽株式会社 Composition and method for diagnosis or detection of gastric cancer
CN102196823A (en) * 2008-09-12 2011-09-21 日东电工株式会社 Imaging agents of fibrotic diseases
CN102388307A (en) * 2008-11-12 2012-03-21 耶达研究与发展有限公司 Diagnosis of multiple sclerosis
CN102405236A (en) * 2009-02-19 2012-04-04 葛兰素集团有限公司 Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
CN102812348A (en) * 2009-12-22 2012-12-05 新加坡科技研究局 SERS-based Analyte Detection
CN103237901A (en) * 2010-03-01 2013-08-07 卡里斯生命科学卢森堡控股有限责任公司 Biomarkers for theranostics
CN103025890A (en) * 2010-04-06 2013-04-03 卡里斯生命科学卢森堡控股 Circulating biomarkers for disease
CN105683757A (en) * 2013-08-20 2016-06-15 开普敦大学 Method for diagnosing tuberculosis in urine samples
CN106164089A (en) * 2014-04-02 2016-11-23 日东电工株式会社 Targeted molecular and application thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRANDY L. YOUNG ET AL.: "The identification of tuberculosis biomarkers in human urine sample", 《EUROPEAN RESPIRATORY JOURNAL》 *
GENEBANK: "retinol-binding protein 4 precursor [Pan troglodytes] NCBI Reference Sequence: NP_001038960.1", 《GENEBANK》 *
UNIPROTKB: "UniProtKB-P02753(RET4_HUMAN)", 《UNIPROTKB》 *
王洁茹: "肺结核病新型诊断标识的筛选及两种重要分子调控巨噬细胞炎性反应机制研究", 《中国博士学位论文全文数据库 农业科技辑》 *
麦洪珍 等: "肺结核患者血清维生素A、视黄醇结合蛋白4水平及其对耐药性的影响", 《中国防痨杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024092169A3 (en) * 2022-10-27 2024-06-06 Cz Biohub Sf, Llc Lower respiratory tract infections

Similar Documents

Publication Publication Date Title
CN105934670B (en) Method for detaching excretion body
JP2015511002A (en) Multi-biomarker set for breast cancer diagnosis, detection method thereof, and breast cancer diagnosis kit including antibody thereto
KR20150044834A (en) Selection of preferred sample handling and processing protocol for identification of disease biomarkers and sample quality assessment
CN104764885A (en) An early-stage screening kit for diabetic nephropathy, a biomarker detecting method and applications
CN101424661B (en) Serodiagnosis model establishing method for active tuberculosis disease
CN204479594U (en) Based on the diabetic nephropathy early detection kit of biomarker
CN105467123A (en) Early diagnosis marker screening system and joint detection kit for pulmonary fibrosis
JP2013507618A (en) Anti-VLA-4 related assays
CN204479593U (en) Based on the injury of kidney detection kit of biomarker
US20120214177A1 (en) Methods and compositions for diagnosis of urosepsis and urinary tract infection
CN102221607A (en) Antibody composition and application thereof
Zhang et al. Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis
CN107043413A (en) A kind of related urinary biomarkers albumen of pulmonary tuberculosis and its application
CA2993102A1 (en) Biomarker combinations for prostate disease
JP2024529555A (en) Biomarkers for predicting or monitoring recurrence of NMOSD and their uses
CN113125757B (en) Protein biomarker for early pregnancy diagnosis of sows and method for detecting early pregnancy of sows by using protein biomarker
CN109580931A (en) A kind of α 1- microglobulin detection kit
Demirel et al. Comparison of sysmex UF-5000 flow cytometer and fuchs-rosenthal chamber urine sediment analysis
CN112630432A (en) Application of FLNA, FBLN1 and TSP-1 as markers in preparation of asbestos-related disease detection kit
CN108957013B (en) IGLON5 and SERPINB13 proteins associated with osteoarthritis and application thereof
CN112285360A (en) Application of I-309 in preparation of primary sicca syndrome diagnostic reagent or kit
RU2524422C1 (en) Diagnostic technique for hyperparathyroidism
CN107643283B (en) Application of interferon-induced T cell α chemokine in preparation of primary biliary cholangitis diagnostic reagent or kit
CN109374904A (en) A kind of protein-based sepsis markers and its in the application of severe sepsis early warning and its screening technique
WO2007148720A1 (en) Protein associated with nephrotic syndrome and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170815